NASDAQ:CHRS - Coherus Biosciences Stock Price, Forecast & News

Coherus Biosciences trades on the NASDAQ under the ticker symbol "CHRS."

Coherus Biosciences Inc (NASDAQ:CHRS) announced its quarterly earnings results on Wednesday, November, 6th. The biotechnology company reported $0.63 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.36 by $0.27. The biotechnology company earned $111.68 million during the quarter, compared to analyst estimates of $93.58 million. View Coherus Biosciences' Earnings History.

Coherus Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Coherus Biosciences.

Coherus Biosciences will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

7 brokers have issued 12-month target prices for Coherus Biosciences' stock. Their forecasts range from $27.00 to $43.00. On average, they expect Coherus Biosciences' stock price to reach $32.71 in the next twelve months. This suggests a possible upside of 53.6% from the stock's current price. View Analyst Price Targets for Coherus Biosciences.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Coherus Biosciences in the last year. There are currently 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Coherus Biosciences.

Media coverage about CHRS stock has trended somewhat negative recently, according to InfoTrie Sentiment. The research group scores the sentiment of press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Coherus Biosciences earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned news coverage about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the near future. View News Stories for Coherus Biosciences.

Coherus Biosciences saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 10,770,000 shares, an increase of 7.2% from the January 15th total of 10,050,000 shares. Based on an average trading volume of 1,040,000 shares, the days-to-cover ratio is currently 10.4 days. Approximately 16.9% of the company's stock are short sold. View Coherus Biosciences' Current Options Chain.

Some companies that are related to Coherus Biosciences include argenx (ARGX), Repligen (RGEN), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Spark Therapeutics (ONCE), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT), Ablynx (ABLYF), Crispr Therapeutics (CRSP), Momenta Pharmaceuticals (MNTA), Halozyme Therapeutics (HALO), Iovance Biotherapeutics (IOVA), Allogene Therapeutics (ALLO), Audentes Therapeutics (BOLD) and Fate Therapeutics (FATE).

Based on aggregate information from My MarketBeat watchlists, some companies that other Coherus Biosciences investors own include Chembio Diagnostics (CEMI), Halozyme Therapeutics (HALO), Intelsat (I), Exelixis (EXEL), Bank of America (BAC), Immunomedics (IMMU), Heron Therapeutics (HRTX), Progenics Pharmaceuticals (PGNX), Fossil Group (FOSL) and Sangamo Therapeutics (SGMO).

Coherus Biosciences' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Temasek Holdings Private Ltd (10.53%), State Street Corp (4.97%), Lord Abbett & CO. LLC (4.38%), Alliancebernstein L.P. (3.11%), UBS Asset Management Americas Inc. (2.73%) and Goldman Sachs Group Inc. (2.02%). Company insiders that own Coherus Biosciences stock include Barbara K Finck, Dennis M Lanfear, James Healy, Jean-Frederic Viret and Vincent R Anicetti. View Institutional Ownership Trends for Coherus Biosciences.

CHRS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Partner Fund Management L.P., First Trust Advisors LP, Chartwell Investment Partners LLC, Credit Suisse AG, 361 Capital LLC, PNC Financial Services Group Inc. and Russell Investments Group Ltd.. Company insiders that have sold Coherus Biosciences company stock in the last year include Dennis M Lanfear, James Healy, Jean-Frederic Viret and Vincent R Anicetti. View Insider Buying and Selling for Coherus Biosciences.

CHRS stock was bought by a variety of institutional investors in the last quarter, including Alliancebernstein L.P., Temasek Holdings Private Ltd, State Street Corp, Hawk Ridge Capital Management LP, Goldman Sachs Group Inc., UBS Asset Management Americas Inc., Charles Schwab Investment Management Inc. and Panagora Asset Management Inc.. View Insider Buying and Selling for Coherus Biosciences.

Shares of CHRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of CHRS stock can currently be purchased for approximately $21.30.

Coherus Biosciences has a market capitalization of $1.49 billion and generates $1.56 million in revenue each year. The biotechnology company earns $-209,340,000.00 in net income (profit) each year or ($3.22) on an earnings per share basis. Coherus Biosciences employs 232 workers across the globe.View Additional Information About Coherus Biosciences.

The official website for Coherus Biosciences is http://www.coherus.com/.

Coherus Biosciences' mailing address is 333 TWIN DOLPHIN DRIVE SUITE 600, REDWOOD CITY CA, 94065. The biotechnology company can be reached via phone at 650-649-3530 or via email at [email protected]